| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1985PNAS...82.2173J |
| P356 | DOI | 10.1073/PNAS.82.7.2173 |
| P8608 | Fatcat ID | release_e45bdeu4nfewli4ekxnksdxz64 |
| P932 | PMC publication ID | 397515 |
| P698 | PubMed publication ID | 3872460 |
| P5875 | ResearchGate publication ID | 19288399 |
| P50 | author | Solomon Halbert Snyder | Q1681665 |
| Stephen M. Strittmatter | Q37622118 | ||
| P2093 | author name string | R J D'Amato | |
| J A Javitch | |||
| P2860 | cites work | Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors | Q48614146 |
| Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism | Q48614154 | ||
| Brain enzyme is the target of drug toxin | Q48621296 | ||
| N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigrostriatal lesion in the rat | Q48643295 | ||
| Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart | Q48644682 | ||
| High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase | Q48645342 | ||
| 3Hmazindol binding associated with neuronal dopamine and norepinephrine uptake sites | Q48655318 | ||
| Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice | Q48655550 | ||
| Reduction of dopamine uptake and cocaine binding in mouse striatum by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q48656967 | ||
| Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones | Q48661552 | ||
| Acute administration of 1-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a compound producing parkinsonism in humans, stimulates [2-14C]deoxyglucose uptake in the regions of the catecholaminergic cell bodies in the rat and guinea pig brains | Q48667506 | ||
| Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase | Q48681443 | ||
| Neurochemical and behavioral effects of systematic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat | Q48682433 | ||
| Specificity of antisera prepared against pure bovine MAO-B. | Q48726435 | ||
| Characterization of [3H]desipramine binding associated with neuronal norepinephrine uptake sites in rat brain membranes | Q48890406 | ||
| Quantitative receptor autoradiography using [3H]ultrofilm: application to multiple benzodiazepine receptors | Q48931198 | ||
| Localization of catecholamine uptake in rat brain slices. | Q51261125 | ||
| The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man | Q64762153 | ||
| A practical computer-based approach to the analysis of radioligand binding experiments | Q70184046 | ||
| Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse | Q71002559 | ||
| Quantitative autoradiography of [3H]MPTP binding sites in rat brain | Q71008199 | ||
| Protein measurement with the Folin phenol reagent | Q20900776 | ||
| Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis | Q22242250 | ||
| 1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra | Q28266104 | ||
| Pargyline Prevents MPTP-Induced Parkinsonism in Primates | Q28266115 | ||
| Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey | Q28270776 | ||
| Chronic parkinsonism secondary to intravenous injection of meperidine analogues | Q28323857 | ||
| Blockade of monoamine uptake by 1-amino-4-phenylbicyclo(2,2,2)octane (EXP 561) in rat brain and heart | Q28330554 | ||
| Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain | Q36273938 | ||
| Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons | Q36317322 | ||
| The brain-stem lesions in Parkinsonism | Q37272987 | ||
| A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Q37343442 | ||
| Citalopram — Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity | Q40088615 | ||
| Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease | Q42252802 | ||
| Barbiturate recognition site on the GABA/benzodiazepine receptor complex is distinct from the picrotoxinin/TBPS recognition site | Q48602057 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| dopamine | Q170304 | ||
| P304 | page(s) | 2173-2177 | |
| P577 | publication date | 1985-04-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity | |
| P478 | volume | 82 |
| Q72549636 | 1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol inhibits tyrosine hydroxylase activity in rat striatal synaptosomes |
| Q44462590 | 1-Benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ), an endogenous neurotoxin, induces dopaminergic cell death through apoptosis |
| Q41142735 | 1-Methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells is enhanced by preventing glycolysis |
| Q41722444 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine- and 1-methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells: role of monoamine oxidase A. |
| Q35844507 | 1-Methyl-4-phenylpyridinium induces synaptic dysfunction through a pathway involving caspase and PKCdelta enzymatic activities. |
| Q44046048 | 1-Methyl-4-phenylpyridinium ion, a toxin that can cause parkinsonism, alters branched structures of DNA. |
| Q51757220 | 1-Methyl-4-phenylpyridinium uptake by human and rat striatal synaptosomes |
| Q44748873 | 1-Methyl-4-phenylpyridinium-induced apoptosis in cerebellar granule neurons is mediated by transferrin receptor iron-dependent depletion of tetrahydrobiopterin and neuronal nitric-oxide synthase-derived superoxide |
| Q40623645 | 1-Methyl-4-phenylpyridinium-induced down-regulation of dopamine transporter function correlates with a reduction in dopamine transporter cell surface expression |
| Q40152277 | 1-methyl-4-phenylpyridinium-induced alterations of glutathione status in immortalized rat dopaminergic neurons |
| Q44441344 | 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine Pretreatment Attenuates Methamphetamine‐Induced Dopamine Toxicity |
| Q36692394 | 2, 2'- and 4, 4'-Cyanines are transporter-independent in vitro dopaminergic toxins with the specificity and mechanism of toxicity similar to MPP⁺. |
| Q48555516 | 21-aminosteroids interact with the dopamine transporter to protect against 1-methyl-4-phenylpyridinium-induced neurotoxicity |
| Q34459984 | 3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter |
| Q35754644 | A Physical Interaction between the Dopamine Transporter and DJ-1 Facilitates Increased Dopamine Reuptake |
| Q48225833 | A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| Q46896514 | A model of MPTP-induced Parkinson's disease in the goldfish |
| Q31637907 | A new in vitro approach for investigating the MPTP effect on DA uptake |
| Q28323156 | A review of the pharmacology of selegiline |
| Q36851667 | APP+, a fluorescent analogue of the neurotoxin MPP+, is a marker of catecholamine neurons in brain tissue, but not a fluorescent false neurotransmitter |
| Q42504998 | Acetylcholinesterase inhibition by 1-methyl-4-phenylpyridinium ion, a bioactivated metabolite of MPTP. |
| Q44865034 | Acute exposure to organochlorine pesticides does not affect striatal dopamine in mice |
| Q48188310 | Acute interactions between L-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in mice. |
| Q40690704 | Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells |
| Q35092815 | Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys |
| Q28204386 | Alpha-synuclein and neurodegenerative diseases |
| Q44230508 | Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. |
| Q40603141 | Amphetamine regulation of dopamine transport. Combined measurements of transporter currents and transporter imaging support the endocytosis of an active carrier. |
| Q26823690 | An Alternative Medical Approach for the Neuroprotective Therapy to Slow the Progression of Parkinson's Disease |
| Q35755898 | An in vitro model of 1-methyl-4-phenyl-pyridinium (MPP+) toxicity: incubation of rabbit caudate nucleus slices with MPP+ followed by biochemical and functional analysis |
| Q34596189 | Animal models of Parkinson's disease. |
| Q38155480 | Animal models of Parkinson's disease: a gateway to therapeutics? |
| Q35589979 | Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. |
| Q36235578 | Animal models of the non-motor features of Parkinson's disease |
| Q33280786 | Apoptotic mode of cell death in substantia nigra following intranigral infusion of the parkinsonian neurotoxin, MPP+ in Sprague-Dawley rats: cellular, molecular and ultrastructural evidences |
| Q34476384 | Are Dopamine, Norepinephrine, and Serotonin Precursors of Biologically Reactive Intermediates Involved in the Pathogenesis of Neurodegenerative Brain Disorders? |
| Q43748726 | Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP. |
| Q38200488 | Association of glycogen synthase kinase-3β with Parkinson's disease (review). |
| Q89523502 | Astrocyte-Derived Exosomal microRNA miR-200a-3p Prevents MPP+-Induced Apoptotic Cell Death Through Down-Regulation of MKK4 |
| Q34168266 | Astrocytes and Therapeutics for Parkinson's Disease |
| Q53437162 | Astroglial DJ-1 over-expression up-regulates proteins involved in redox regulation and is neuroprotective in vivo |
| Q40681349 | Binding and transport in norepinephrine transporters. Real-time, spatially resolved analysis in single cells using a fluorescent substrate |
| Q44076211 | Biodistribution study of [99mTc] TRODAT-1 alone or combined with other dopaminergic drugs in mice with macroautoradiography |
| Q36197809 | Biogenic amine neurotransmitter transporters: just when you thought you knew them. |
| Q91959308 | Biological bases for a possible effect of cannabidiol in Parkinson's disease |
| Q38163490 | Brain enzymes as receptors: angiotensin-converting enzyme and enkephalin convertase |
| Q48459449 | Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system |
| Q94453416 | C. elegans and Neurodegeneration In Caenorhabditis Elegans: Anatomy, Life Cycles and Biological Functions |
| Q73824869 | C. elegans: a novel pharmacogenetic model to study Parkinson's disease |
| Q46890595 | Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. |
| Q43656845 | Carrier-mediated processes in blood--brain barrier penetration and neural uptake of paraquat |
| Q37376117 | Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps |
| Q33515197 | Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). |
| Q44556341 | Cerebral metabolic effects of monoamine oxidase inhibition in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine acutely treated monkeys |
| Q35172603 | Changes in neuronal dopamine homeostasis following 1-methyl-4-phenylpyridinium (MPP+) exposure |
| Q36349365 | Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine |
| Q58715913 | Characteristics of the mitochondrial and cellular uptake of MPP+, as probed by the fluorescent mimic, 4'I-MPP |
| Q41914198 | Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin |
| Q89520027 | Chronic Systemic Inflammation Exacerbates Neurotoxicity in a Parkinson's Disease Model |
| Q48729263 | Chronic exposure to Ro20-1724 protects dopaminergic neurons in vitro against the neurotoxic action of N-methyl-D-aspartate and 1-methyl-4-phenylpyridinium |
| Q42436464 | Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats |
| Q30397145 | Classic Studies on the Interaction of Cocaine and the Dopamine Transporter |
| Q35875871 | Classic and New Animal Models of Parkinson's Disease |
| Q36773385 | Clavulanic acid inhibits MPP⁺-induced ROS generation and subsequent loss of dopaminergic cells |
| Q38668883 | Clues to the mechanism underlying dopamine cell death in Parkinson's disease |
| Q51430696 | Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression |
| Q53071097 | Comparative analysis of Parkinson's disease-associated genes reveals altered survival and bioenergetics of parkin-deficient dopamine neurons in mice |
| Q48587566 | Comparison of Key Steps in 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) Neurotoxicity in Rodents |
| Q36349464 | Comparison of MPTP and amphetamines as dopaminergic neurotoxins |
| Q41286489 | Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells |
| Q36373173 | Complete Comparison Display (CCD) evaluation of ethanol extracts of Centella asiatica and Withania somnifera shows that they can non-synergistically ameliorate biochemical and behavioural damages in MPTP induced Parkinson's model of mice |
| Q47658773 | Computer-aided drug design applied to Parkinson targets |
| Q34625772 | Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity |
| Q35919815 | D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease |
| Q49146450 | DNA damage in brain mitochondria caused by aging and MPTP treatment |
| Q41033396 | Death by a dopaminergic neurotoxin, 1-methyl-4-phenylpyridinium ion (MPP+) and protection by EGF in GH3 cells |
| Q34957441 | Decreased expression of organic cation transporters, Oct1 and Oct2, in brain microvessels and its implication to MPTP-induced dopaminergic toxicity in aged mice |
| Q43640148 | Decreased expression of the NADH:ubiquinone oxidoreductase (complex I) subunit 4 in 1-methyl-4-phenylpyridinium -treated human neuroblastoma SH-SY5Y cells |
| Q37262975 | Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems. |
| Q44602402 | Delayed Onset of Oculogyric Crisis and Torticollis with Intramuscular Haloperidol |
| Q30310797 | Dependence on electron transport chain function and intracellular signaling of genomic responses in SH-SY5Y cells to the mitochondrial neurotoxin MPP+ |
| Q48431775 | Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. |
| Q67884630 | Determination of an irreversible inhibitor of monoamine oxidase B (MDL 72974A) in human plasma and urine by gas chromatography—positive-ion chemical ionization mass spectrometry |
| Q64996327 | Development of a Competition-Binding Assay to Determine Binding Affinity of Molecules to Neuromelanin via Fluorescence Spectroscopy. |
| Q73472949 | Differential effect of structural modification of human dopamine transporter on the inward and outward transport of dopamine |
| Q48519851 | Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse |
| Q44583355 | Differential effects of carboxyfullerene on MPP+/MPTP-induced neurotoxicity |
| Q48241892 | Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP. |
| Q40796014 | Differentiation of embryonic stem cell-derived dopaminergic neurons is enhanced by survival-promoting factors. |
| Q48576376 | Dimethoxyphenylethylamine and tetrahydropapaverine are toxic to the nigrostriatal system |
| Q36065503 | Diquat causes caspase-independent cell death in SH-SY5Y cells by production of ROS independently of mitochondria |
| Q36505602 | Direct intranigral injection of dopaminochrome causes degeneration of dopamine neurons |
| Q35040174 | Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. |
| Q34389592 | Discovery of a neuroprotective chemical, (S)-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(-)-P7C3-S243], with improved druglike properties |
| Q41261577 | Dissection of dopamine and cocaine binding sites on the rat dopamine transporter expressed in COS cells |
| Q37076753 | Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum |
| Q24314400 | Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter |
| Q44072410 | Distribution of catecholamine uptake sites in human brain as determined by quantitative [3H] mazindol autoradiography |
| Q40223933 | Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation |
| Q54579499 | Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ -induced toxicity in PC12 cells. |
| Q40582032 | Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity |
| Q37242658 | Dopamine transporter genetic variants and pesticides in Parkinson's disease |
| Q48189864 | Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra |
| Q33739406 | Dopamine transporters and neuronal injury |
| Q34320761 | Dopamine uptake sites in the striatum are distributed differentially in striosome and matrix compartments |
| Q74744617 | Dose-related inversion of cinnarizine and flunarizine effects on mitochondrial permeability transition |
| Q28331035 | Drug-induced parkinsonism and other movement disorders |
| Q41376219 | Dynamic Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson's Disease |
| Q45030456 | Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra. |
| Q43902560 | EGb761 blocks MPP+-induced lipid peroxidation in mouse corpus striatum |
| Q44940736 | EGb761 pretreatment reduces monoamine oxidase activity in mouse corpus striatum during 1-methyl-4-phenylpyridinium neurotoxicity. |
| Q48500620 | Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in goldfish cerebellum: neurochemical and immunocytochemical analysis |
| Q42449987 | Effect of 1-methyl-4-phenylpyridinium (MPP+) on mitochondrial membrane potential in cerebellar neurons: interaction with the NMDA receptor. |
| Q42142080 | Effect of L-arginine/nitric oxide pathway on MPP(+)-induced cell injury in the striatum of rats |
| Q48291787 | Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites |
| Q70959236 | Effect of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain slices |
| Q31454734 | Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. |
| Q83638234 | Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on retinal dopaminergic system in mice |
| Q48078497 | Effects of Agmatine on Depressive-Like Behavior Induced by Intracerebroventricular Administration of 1-Methyl-4-phenylpyridinium (MPP(+)). |
| Q44258713 | Effects of green tea polyphenols on dopamine uptake and on MPP+ -induced dopamine neuron injury |
| Q45110937 | Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia |
| Q28194974 | Effects of some antioxidative aporphine derivatives on striatal dopaminergic transmission and on MPTP-induced striatal dopamine depletion in B6CBA mice |
| Q41661302 | Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease |
| Q26795417 | Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics |
| Q90589159 | Emerging novel approaches to drug research and diagnosis of Parkinson's disease |
| Q28389950 | Energy failure: does it contribute to neurodegeneration? |
| Q46991332 | Enhanced serotonin transporter function during depression in seasonal affective disorder |
| Q28074723 | Environmental Exposures and Parkinson's Disease |
| Q54940595 | Environmental and Genetic Variables Influencing Mitochondrial Health and Parkinson's Disease Penetrance. |
| Q33349701 | Environmental exposure, obesity, and Parkinson's disease: lessons from fat and old worms |
| Q34995010 | Environmental factors in Parkinson's disease |
| Q30405933 | Enzymatic oxidation of xenobiotic chemicals |
| Q64781357 | Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female, but not male rats |
| Q26772843 | Evaluation of Models of Parkinson's Disease |
| Q48594958 | Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis |
| Q28145614 | Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure |
| Q34207470 | Evidence of oligodendrogliosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism. |
| Q44479868 | Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease |
| Q37880198 | Expanding morphological dimensions in neuropathology, from sequence biology to pathological sequences and clinical consequences |
| Q24296225 | Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter |
| Q48542762 | Expression of c-Jun in dopaminergic neurons of the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice |
| Q45081906 | Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons |
| Q41232514 | Expression of the extraneuronal monoamine transporter (uptake2) in human glioma cells |
| Q36349469 | Features of the dopaminergic neurotoxin MPTP. |
| Q42391380 | FosB and ΔFosB expression in brain regions containing differentially susceptible dopamine neurons following acute neurotoxicant exposure |
| Q72670526 | Functional changes in cocultures of mesencephalon and striatal neurons from embryonic C57/BL6 mice due to low concentrations of 1-methyl-4-phenylpyridinium (MPP+) |
| Q31900813 | GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets |
| Q37078997 | GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism |
| Q36069691 | Gene expression in the Parkinson's disease brain |
| Q33191656 | Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium |
| Q26863375 | Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models |
| Q41056504 | Glutamate and Parkinson's disease |
| Q37585401 | Glutamate receptors as therapeutic targets for Parkinson's disease |
| Q32034638 | Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction |
| Q40923586 | HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine (MPP+) via impairment of energy metabolism |
| Q36901616 | Helix XI contributes to the entrance of the serotonin transporter permeation pathway |
| Q46304872 | Heterogeneity of electrically evoked dopamine release and reuptake in substantia nigra, ventral tegmental area, and striatum |
| Q33507513 | Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease |
| Q48914770 | Hypoxia-Induced Neurotransmitter Deficits in Neonatal Rats Are Partially Corrected by Exogenous GM1 Ganglioside |
| Q30994096 | Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. |
| Q33641852 | Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| Q36958913 | In vivo distribution of catecholamine reuptake sites in human brain gives clues to the physiopathology of MPTP-induced parkinsonism |
| Q27308109 | Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. |
| Q44878442 | Increased striatal dopamine turnover following acute administration of rotenone to mice |
| Q48273713 | Increased striatal lipid peroxidation after intracerebroventricular MPP+ administration to mice |
| Q44418553 | Increased synaptosomal dopamine content and brain concentration of paraquat produced by selective dithiocarbamates |
| Q41724335 | Infection with Murine Retrovirus Confers Resistance to the Neurotoxin 1-Methyl-4-Phenylpyridinium Ion in PC12 Cells |
| Q40958950 | Influence of MPP+ on the state of tubulin polymerisation in NGF-differentiated PC12 cells |
| Q24552403 | Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporter |
| Q44451960 | Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. |
| Q42824368 | Inhibition of complex I by hydrophobic analogues of N-methyl-4-phenylpyridinium (MPP+) and the use of an ion-selective electrode to measure their accumulation by mitochondria and electron-transport particles |
| Q59794168 | Integrated Proteomics and Lipidomics Investigation of the Mechanism Underlying the Neuroprotective Effect of -benzylhexadecanamide |
| Q42025081 | Interaction of 1-methyl-4-phenylpyridinium ion and tyramine with a site putatively involved in the striatal vesicular release of dopamine |
| Q42853435 | Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases |
| Q41738674 | Invited Review Free radicals and the pathobiology of brain dopamine systems |
| Q71699825 | Inward transport of 3H-MPP+ in freshly isolated rat hepatocytes: evidence for interaction with catecholamines |
| Q94544758 | Isoproterenol-Dependent Activation of TRPM7 Protects Against Neurotoxin-Induced Loss of Neuroblastoma Cells |
| Q34475645 | Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease |
| Q44572684 | Kainic acid lesion-induced nigral neuronal death |
| Q36131925 | L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain. |
| Q48794195 | Less induced 1-methyl-4-phenylpyridinium ion neurotoxicity on striatal slices from guinea-pigs fed with a vitamin C-deficient diet |
| Q46503658 | Lipophilic Cationic Cyanines Are Potent Complex I Inhibitors and Specific in Vitro Dopaminergic Toxins with Mechanistic Similarities to Both Rotenone and MPP(.). |
| Q64821231 | Local striatal infusion of MPP+ does not result in increased hydroxylation after systemic administration of 4-hydroxybenzoate |
| Q83032674 | Loss of striatal dopaminergic terminals during the early stage in response to MPTP injection in C57BL/6 mice |
| Q48450578 | Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice |
| Q48446938 | MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates |
| Q41008578 | MPP+ toxicity and plasma membrane dopamine transporter: study using cell lines expressing the wild-type and mutant rat dopamine transporters |
| Q48483209 | MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions. |
| Q48561566 | MPTP Produces Differential Oxidative Stress and Antioxidative Responses in the Nigrostriatal and Mesolimbic Dopaminergic Pathways |
| Q36129331 | MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview |
| Q35891901 | MPTP as a mitochondrial neurotoxic model of Parkinson's disease |
| Q38021200 | MPTP induced parkinsonian syndrome: long term follow-up and neurophysiological study. |
| Q52168653 | MPTP selectively induces haem oxygenase-1 expression in striatal astrocytes |
| Q48526816 | MPTP-Parkinsonism is accompanied by persistent expression of a Δ-FosB-like protein in dopaminergic pathways |
| Q37724147 | MPTP-induced neurotoxicity and the quest for a preventative therapy for Parkinson's disease |
| Q34802076 | MPTP: insights into parkinsonian neurodegeneration |
| Q42175955 | Magnolol Protects against MPTP/MPP(+)-Induced Toxicity via Inhibition of Oxidative Stress in In Vivo and In Vitro Models of Parkinson's Disease |
| Q46714295 | Mechanism of 1-methyl-4-phenylpyridinium-induced dopamine release from PC12 cells |
| Q48860182 | Mechanism of resistance to NO-induced neurotoxicity in cultured rat dopaminergic neurons |
| Q39247520 | Mechanisms of Gene-Environment Interactions in Parkinson's Disease |
| Q43796457 | Mechanisms of MPP(+) incorporation into cerebellar granule cells |
| Q27333086 | Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain |
| Q46742263 | Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats |
| Q38926644 | Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease |
| Q46905324 | Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra. |
| Q41484307 | Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B. |
| Q45151001 | Methyl Yellow: A Potential Drug Scaffold for Parkinson's Disease |
| Q43660109 | Methyl-4-phenylpyridinium (MPP(+))-evoked dopamine release from rat striatal slices: possible roles of voltage-dependent calcium channels and reverse dopamine transport |
| Q40698227 | Methylenedioxymethamphetamine inhibits mitochondrial complex I activity in mice: a possible mechanism underlying neurotoxicity |
| Q26773064 | Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice |
| Q44600306 | Minocycline enhances MPTP toxicity to dopaminergic neurons |
| Q36545033 | Mitochondria: new drug targets for oxidative stress-induced diseases |
| Q33364885 | Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease |
| Q30446972 | Mitochondrial Dysfunction in Idiopathic Parkinson Disease |
| Q34460675 | Mitochondrial Dysfunction in Parkinson's Disease: Pathogenesis and Neuroprotection |
| Q89697766 | Mitochondrial E3 Ubiquitin Ligase Parkin: Relationships with Other Causal Proteins in Familial Parkinson's Disease and Its Substrate-Involved Mouse Experimental Models |
| Q69370277 | Mitochondrial complex I deficiency in Parkinson's disease |
| Q38811534 | Mitochondrial control of cell bioenergetics in Parkinson's disease. |
| Q33840243 | Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis |
| Q36349422 | Mitochondrial mechanisms of neurotoxicity |
| Q38370162 | Mitochondrial mechanisms of redox cycling agents implicated in Parkinson's disease |
| Q30471061 | Mitochondrial toxins in models of neurodegenerative diseases. I: in vivo brain hydroxyl radical production during sytemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions |
| Q30471062 | Mitochondrial toxins in models of neurodegenerative diseases. II: elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment |
| Q36797994 | Model fusion, the next phase in developing animal models for Parkinson's disease |
| Q32133977 | Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes |
| Q40694546 | Modulation of uptake of organic cationic drugs in cultured human colon adenocarcinoma Caco-2 cells by an ecto-alkaline phosphatase activity. |
| Q68329869 | Molecular determinants in the bioactivation of the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) |
| Q82447194 | Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: Evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO |
| Q34328668 | Molecular neurotoxicological models of Parkinsonism: focus on genetic manipulation of mice |
| Q38213838 | Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy |
| Q48182138 | Monoamine oxidase in the intermediolateral nucleus of the thoracic spinal cord of the rat. A histochemical study |
| Q35165280 | Monoamine reuptake inhibitors in Parkinson's disease |
| Q35091143 | N-terminal tagging of the dopamine transporter impairs protein expression and trafficking in vivo. |
| Q36984476 | Near-infrared light via light-emitting diode treatment is therapeutic against rotenone- and 1-methyl-4-phenylpyridinium ion-induced neurotoxicity |
| Q38078895 | Neural and immune mechanisms in the pathogenesis of Parkinson's disease. |
| Q28748883 | Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate |
| Q46723175 | Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity |
| Q36045259 | Neurodegeneration and neuroprotection in Parkinson disease |
| Q48188803 | Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. |
| Q58737028 | Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches |
| Q36994301 | Neurodegenerative diseases: neurotoxins as sufficient etiologic agents? |
| Q37978305 | Neurogenesis in Neurotoxin-induced Animal Models for Parkinson's Disease-A Review of the Current Status |
| Q34169019 | Neuromelanin in the human brain: a review and atlas of pigmented cells in the substantia nigra |
| Q48139739 | Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey |
| Q48434037 | Neuroprotection by bromocriptine against 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced neurotoxicity in mice1 |
| Q42710028 | Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson's disease |
| Q38742688 | Neuroprotective Effect of Low-Intensity Pulsed Ultrasound Against MPP+-Induced Neurotoxicity in PC12 Cells: Involvement of K2P Channels and Stretch-Activated Ion Channels |
| Q92082321 | Neuroprotective Effect of Schisandra Chinensis on Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonian Syndrome in C57BL/6 Mice |
| Q48399826 | Neuroprotective Effects of Longan (Dimocarpus longan Lour.) Flower Water Extract on MPP+-Induced Neurotoxicity in Rat Brain |
| Q30525849 | Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease |
| Q40027470 | Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues |
| Q48201304 | Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys |
| Q68103579 | Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+ |
| Q48726366 | Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture |
| Q33708283 | Neurotoxic in vivo models of Parkinson's disease recent advances. |
| Q43679571 | Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update |
| Q37959729 | Neurotoxin-based models of Parkinson's disease |
| Q35858131 | Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling |
| Q30476174 | Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans |
| Q40653060 | Neurotrophins and their receptors in nerve injury and repair. |
| Q33783000 | New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders |
| Q30497542 | Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, α synuclein aggregation, oxidative damage and behavioral changes |
| Q52563440 | Nitric Oxide Donors Protect Cultured Rat Astrocytes From 1-Methyl-4-Phenylpyridinium-Induced Toxicity |
| Q36389388 | Nitric oxide and MPP+-induced hydroxyl radical generation |
| Q35044809 | Nitric oxide inhibits uptake of dopamine and N-methyl-4-phenylpyridinium (MPP+) but not release of MPP+ in rat C6 glioma cells expressing human dopamine transporter |
| Q37785104 | Nitrosylation and nitration of mitochondrial complex I in Parkinson's disease. |
| Q67228552 | No NO prevents parkinsonism |
| Q93048295 | Novel Synthesis of Substituted 2-Trifluoromethyl and 2-Perfluoroalkyl N-Arylpyridinium Compounds-Mechanistic Insights |
| Q38016374 | Oxidative damage to RNA in aging and neurodegenerative disorders |
| Q46252606 | Oxidative stress and cellular pathologies in Parkinson's disease. |
| Q40538595 | Oxidative stress in Parkinson's disease |
| Q42475172 | Oxidative stress induced by MPTP and MPP(+): selective vulnerability of cultured mouse astrocytes |
| Q37452873 | Oxygen free radicals and brain dysfunction |
| Q34540736 | P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases |
| Q44213216 | PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice |
| Q37635610 | PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson's Disease Pathobiology? |
| Q50532472 | Pale Neurites, Premature α‐Synuclein Aggregates with Centripetal Extension from Axon Collaterals |
| Q44451299 | Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats |
| Q37238454 | Paraquat is excluded by the blood brain barrier in rhesus macaque: An in vivo pet study |
| Q35651220 | Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. |
| Q34597817 | Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases |
| Q40079867 | Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity |
| Q37953288 | Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease |
| Q67583878 | Parkinson's disease |
| Q81044910 | Parkinson's disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study |
| Q69891824 | Parkinson's disease and pesticides |
| Q82029365 | Parkinson's disease: animal models |
| Q29547424 | Parkinson's disease: mechanisms and models |
| Q64864829 | Parkinson's disease: what the model systems have taught us so far |
| Q26269955 | Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein |
| Q40728188 | Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons. |
| Q43819039 | Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells |
| Q31673344 | Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons |
| Q43616094 | Pharmacological properties of the MPTP analog trans-1-methyl-4-[4-dimethylaminophenylethenyl]-1,2,3,6-tetrahydropyridine and its pyridinium metabolite in mouse brain synaptosomes: a potential visual marker for substrates of MPTP-induced neurotoxicit |
| Q50138266 | Phosphorylation of the Amino Terminus of the Dopamine Transporter: Regulatory Mechanisms and Implications for Amphetamine Action. |
| Q51800931 | Plant-Derived Natural Products for Parkinson's Disease Therapy |
| Q36369850 | Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism |
| Q42211937 | Potent neurotoxic fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs as potential probes in models of Parkinson disease |
| Q91801192 | Potential Benefits of Nobiletin, A Citrus Flavonoid, against Alzheimer's Disease and Parkinson's Disease |
| Q35182956 | Potential therapeutic properties of green tea polyphenols in Parkinson's disease |
| Q41741720 | Potentiation by the tetraphenylboron anion of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its pyridinium metabolite. |
| Q42715484 | Preclinical models of Parkinson's disease. |
| Q43545392 | Predicting Parkinson's disease |
| Q36291772 | Preferential Extracellular Generation of the Active Parkinsonian Toxin MPP+ by Transporter-Independent Export of the Intermediate MPDP+. |
| Q41162106 | Preproenkephalin mRNA and methionine-enkephalin increase in mouse striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment |
| Q41817119 | Prevention by a Ginkgo biloba extract (GBE 761) of the dopaminergic neurotoxicity of MPTP. |
| Q37143657 | Progress in the pathogenesis and genetics of Parkinson's disease |
| Q44006699 | Progressive alteration of neuronal dopamine transporter activity in a rat injured by an intranigral injection of MPP+. |
| Q42532569 | Protection of Primary Dopaminergic Midbrain Neurons by GPR139 Agonists Supports Different Mechanisms of MPP(+) and Rotenone Toxicity |
| Q48358201 | Protective Effect of Talipexole on MPTP-Treated Planarian, a Unique Parkinsonian Worm Model |
| Q45998297 | Protective effects of resveratrol and quercetin against MPP+ -induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. |
| Q34614573 | Protocol for the MPTP mouse model of Parkinson's disease |
| Q44346048 | Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism |
| Q36916051 | Pyridine Derivatives: Structure-Activity Relationships Causing Parkinsonism-Like Symptoms |
| Q48507765 | Quantitation of a mitochondrial DNA deletion in Parkinson's disease |
| Q45269942 | Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease. |
| Q36243860 | Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). |
| Q44451554 | Rapid reduction of ATP synthesis and lack of free radical formation by MPP+ in rat brain synaptosomes and mitochondria |
| Q37753509 | Rational therapeutic approaches to progressive supranuclear palsy |
| Q39337416 | Real-time monitoring of superoxide generation and cytotoxicity in neuroblastoma mitochondria induced by 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline. |
| Q34189660 | Recent advances in the genetics of Parkinson's disease |
| Q48138684 | Recovery of dopaminergic fibers in striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse is enhanced by grafts of adrenal medulla |
| Q88316783 | Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities |
| Q48749612 | Redox modification of Akt mediated by the dopaminergic neurotoxin MPTP, in mouse midbrain, leads to down‐regulation of pAkt |
| Q33810589 | Region-specific protein abundance changes in the brain of MPTP-induced Parkinson's disease mouse model |
| Q28213601 | Regulation of the 75-kDa subunit of mitochondrial complex I by iron |
| Q42039544 | Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition |
| Q48620615 | Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism |
| Q36156158 | Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta |
| Q39338569 | Retroviral-mediated gene transfer. Applications in neurobiology |
| Q36513557 | Review of apoptosis vs. necrosis of substantia nigra pars compacta in Parkinson's disease |
| Q48593473 | Role of Heat Shock Proteins in MPTP‐Induced Neurotoxicity |
| Q44430640 | Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice |
| Q34257471 | Role of alpha-synuclein protein levels in mitochondrial morphology and cell survival in cell lines |
| Q36349357 | Role of astrocytes in MPTP metabolism and toxicity |
| Q31992475 | Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity |
| Q79805436 | Role of mitochondrial dysfunction in Parkinson's disease: Implications for treatment |
| Q37597604 | Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity |
| Q39043644 | Role of neurotoxicants and traumatic brain injury in α-synuclein protein misfolding and aggregation. |
| Q37110410 | Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease |
| Q38131751 | SUMO and Parkinson's disease |
| Q54506747 | Salidroside protects PC12 cells from MPP+-induced apoptosis via activation of the PI3K/Akt pathway |
| Q48004001 | Salsolinol: an Unintelligible and Double-Faced Molecule-Lessons Learned from In Vivo and In Vitro Experiments |
| Q88402191 | Saturation Binding of Nicotine to Synthetic Neuromelanin Demonstrated by Fluorescence Spectroscopy |
| Q41955419 | Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity |
| Q41161444 | Selective and nonselective effects of 1-methyl-4-phenylpyridinium on oxygen consumption in rat striatal and hippocampal slices |
| Q34120276 | Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter |
| Q30955390 | Selective neurotoxins, chemical tools to probe the mind: the first thirty years and beyond |
| Q52740582 | Selective protection of nigral dopaminergic neurons by echinacoside in a rat model of Parkinson disease induced by rotenone |
| Q44438376 | Sequential damage in mitochondrial complexes by peroxidative stress |
| Q43791996 | Sequential up-regulation of the c-fos, c-jun and bax genes in the cortex, striatum and cerebellum induced by a single injection of a low dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in C57BL/6 mice |
| Q48452514 | Serotonergic conversion of MPTP and dopaminergic accumulation of MPP+. |
| Q89586522 | Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease |
| Q71364200 | Short-term manganese pretreatment partially protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity |
| Q38088544 | Sleep disturbances in Parkinson's disease: The contribution of dopamine in REM sleep regulation |
| Q38287291 | Specific up-regulation of GADD153/CHOP in 1-methyl-4-phenyl-pyridinium-treated SH-SY5Y cells |
| Q46884171 | Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP. |
| Q43860478 | Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture |
| Q34322151 | Structural dependence of the inhibition of mitochondrial respiration and of NADH oxidase by 1-methyl-4-phenylpyridinium (MPP+) analogs and their energized accumulation by mitochondria |
| Q47894341 | Structural significance of azaheterocyclic amines related to Parkinson's disease for dopamine transporter |
| Q68795365 | Studies on the mechanism of MPTP oxidation by human liver monoamine oxidase B |
| Q48349404 | Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium |
| Q68789015 | Studies on the uptake of N-methylisoquinolinium ion into rat striatal slices using high-performance liquid chromatography with fluorimetric detection |
| Q34367534 | Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells |
| Q37083453 | Sublethal RNA oxidation as a mechanism for neurodegenerative disease |
| Q35803795 | Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat |
| Q40448429 | Substrate binding stoichiometry and kinetics of the norepinephrine transporter. |
| Q48684704 | Systemic administration of MPTP induces thalamic neuronal degeneration in mice |
| Q48730550 | Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra |
| Q37656913 | TIR-Domain-Containing Adapter-Inducing Interferon-β (TRIF) Is Essential for MPTP-Induced Dopaminergic Neuroprotection via Microglial Cell M1/M2 Modulation |
| Q36530306 | TLR4 Signaling in MPP⁺-Induced Activation of BV-2 Cells |
| Q50999457 | TRPC Channels and Parkinson's Disease |
| Q33757601 | TRPC channels and their implication in neurological diseases |
| Q33797760 | TRPC1 inhibits apoptotic cell degeneration induced by dopaminergic neurotoxin MPTP/MPP(+). |
| Q35675406 | Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse |
| Q52642685 | Targeted deletion of the aquaglyceroporin AQP9 is protective in a mouse model of Parkinson's disease. |
| Q35846770 | Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease |
| Q64759679 | The Gut and Parkinson's Disease-A Bidirectional Pathway. |
| Q48789115 | The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain |
| Q38005634 | The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism |
| Q37796015 | The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future |
| Q48291732 | The N-methyl-D-aspartate antagonist MK-801 fails to protect dopaminergic neurons from 1-methyl-4-phenylpyridinium toxicity in vitro |
| Q46070690 | The Neurotoxin l-Methyl-4-Phenyl-l,2,3,6-Tetrahydropyridine (MPTP): A Key to Parkinson's Disease? |
| Q56474940 | The Role of Active Metabolites in Drug Toxicity |
| Q48408168 | The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys |
| Q72671776 | The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates |
| Q48630162 | The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens |
| Q46546898 | The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model |
| Q35206992 | The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? |
| Q41102124 | The extraneuronal transport mechanism for noradrenaline (uptake2) avidly transports 1-methyl-4-phenylpyridinium (MPP+) |
| Q38139561 | The function of α-synuclein |
| Q40917171 | The goldfish as a drug discovery vehicle for Parkinson's disease and other neurodegenerative disorders |
| Q37998428 | The hypothalamus in MPTP-induced parkinsonism |
| Q33972895 | The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. |
| Q28266471 | The new generation of monoamine oxidase inhibitors |
| Q37194765 | The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway |
| Q30473178 | The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. |
| Q32133943 | The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety |
| Q51081583 | The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways |
| Q34679230 | The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases |
| Q37627941 | The reverse operation of Na(+)/Cl(-)-coupled neurotransmitter transporters--why amphetamines take two to tango. |
| Q45296306 | The role of apoptosis in neurodegenerative diseases |
| Q35551001 | The role of environmental exposures in neurodegeneration and neurodegenerative diseases |
| Q36611426 | The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease |
| Q64767145 | The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss |
| Q28377202 | The toxicity of 6-hydroxydopamine on PC12 and P19 cells |
| Q71765476 | The transport of neurotransmitters into synaptic vesicles |
| Q36052708 | The use of MALDI-MSI in the investigation of psychiatric and neurodegenerative disorders: A review. |
| Q39208290 | The use of nonhuman primate models to understand processes in Parkinson's disease. |
| Q42120615 | Therapeutic effects of hydrogen in animal models of Parkinson's disease. |
| Q48204811 | Topological and chronological features of the impairment of glucose metabolism induced by 1-methyl-4-phenylpyridinium ion (MPP+) in rat brain slices |
| Q47893916 | Toward Serotonin Fluorescent False Neurotransmitters: Development of Fluorescent Dual Serotonin and Vesicular Monoamine Transporter Substrates for Visualizing Serotonin Neurons. |
| Q39160051 | Toxicity of Annonaceae for dopaminergic neurons: potential role in atypical parkinsonism in Guadeloupe. |
| Q28075913 | Toxin-Induced Experimental Models of Learning and Memory Impairment |
| Q72844311 | Treatment of Parkinson's disease |
| Q36372732 | Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease |
| Q37181858 | Unregulated mitochondrial GSK3beta activity results in NADH: ubiquinone oxidoreductase deficiency |
| Q48315993 | Up- and down-expression of the dopamine transporter by plasmid DNA transfer in the rat brain |
| Q42101200 | Uptake and accumulation of 1-methyl-4-phenylpyridinium by rat liver mitochondria measured using an ion-selective electrode |
| Q41065587 | Uptake of 1-methyl-4-phenylpyridinium and dopamine in the mouse brain cell nuclei |
| Q72201126 | Uptake of a neurotoxin-candidate, (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport system |
| Q43691715 | Validity of a quantitative technique to study striatal dopaminergic neurodegeneration by in vivo microdialysis |
| Q28385737 | Vesicular integrity in Parkinson's disease |
| Q24601233 | Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry |
| Q28256325 | Vesicular neurotransmitter transporters. Potential sites for the regulation of synaptic function |
| Q46683287 | Zingerone activates VMAT2 during MPP(+) -induced Cell Death |
| Q38347492 | cDNA microarray analysis of changes in gene expression associated with MPP+ toxicity in SH-SY5Y cells |
| Q36040166 | shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model |
| Q37718542 | trans-Resveratrol as a neuroprotectant. |
| Q38066091 | α-Synuclein Aggregation and Modulating Factors |
| Q64870070 | α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease |
| Q47135899 | α-Synuclein-Dependent Calcium Entry Underlies Differential Sensitivity of Cultured SN and VTA Dopaminergic Neurons to a Parkinsonian Neurotoxin. |
| Q44788856 | α-lipoic acid protects dopaminergic neurons against MPP+-induced apoptosis by attenuating reactive oxygen species formation |
Search more.